Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampin effect on Ataluren PK in healthy subjects
NCT02409004Phase 1Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2015
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ataluren in Duchenne muscular dystrophy (DMD), sponsored by PTC Therapeutics, Inc. Primary endpoints: Area under the plasma concentration versus time curve at 12 days and Maximum plasma concentration at 12 days. Started Feb 2015; status: completed.
02
Drugs
ataluren
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02409004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02409004.